Introduction {#section1-2324709620939802}
============

Progressive multifocal leukoencephalopathy (PML) is a life-threatening infective and demyelinating disease of the central nervous system (CNS), due to the reactivation of polyomavirus John Cunningham virus (JCV).^[@bibr1-2324709620939802]^ PML is usually considered a consequence of immunosuppression,^[@bibr1-2324709620939802]^ following an underlying medical state that affects the immune system directly, or as a result of the use of immunosuppressing medications, thus representing an important concern related to some disease-modifying therapies for multiple sclerosis (MS).^[@bibr1-2324709620939802]^ Several MS treatments have been associated with PML development, including natalizumab, which is responsible for the majority of cases, fingolimod, and dimethyl fumarate.^[@bibr1-2324709620939802],[@bibr2-2324709620939802]^ PML diagnosis requires neurological symptoms, a magnetic resonance imaging (MRI) suggestive of CNS infection, and the presence of JCV-DNA in the cerebrospinal fluid (CSF).^[@bibr3-2324709620939802]^ If the brain MRI is performed in the early PML stages, differentiation from MS lesions can be difficult.^[@bibr4-2324709620939802]^

In this article, we report 2 cases of MS patients showing a radiological picture suggestive for PML, in absence of CSF JCV-DNA positivity.

Case 1 {#section2-2324709620939802}
======

A 42-year-old woman diagnosed with MS in 2003, onset with right optic neuritis, initially treated with interferon-β-1a 44 µg subcutaneously 3 times a week for 9 years, then switched to natalizumab 300 mg intravenously every 28 days, due to high MS activity with more than 2 motor relapses in 12 months and in presence of serum negativity to JCV antibodies. During natalizumab treatment, JCV seroconversion was documented (index = 0.427). After the 24th natalizumab administration, given the PML risk, the patient switched to dimethyl fumarate, after the recommended 3-month washout period. After 17 months of dimethyl fumarate therapy, a routine brain MRI showed few cortico-subcortical hyperintense lesions on T2-weighted images, partly confluent, in the right frontal lobe. One lesion showed contrast enhancement and the findings were suggestive for PML ([Figure 1A](#fig1-2324709620939802){ref-type="fig"}). Treatment was interrupted and the patient underwent lumbar puncture to perform JCV-DNA with high sensitivity test (10 copies of JCV-DNA in 10 µL of CSF), which resulted negative. The remaining cyto-chemical analysis of CSF was normal. Hematological test showed low lymphocytes level (0.850 × 1000 mg/dL). The brain MRI performed 1 month later showed unmodified findings ([Figure 1B](#fig1-2324709620939802){ref-type="fig"}), in absence of contrast enhancement. Neurological examination was stable over time. Brain MRIs were shown to 3 different radiology experts in MS with confirmation of a high radiological suspect of PML. During the next months, the stability of the MRI findings along with the negativity of JCV-DNA copies in the CSF led to revision of the diagnosis of PML and consideration of the right frontal lesions as MS disease activity.

![(A) Few cortico-subcortical hyperintense lesions in the right frontal lobe; T2-weighted (T2W). (B) Brain magnetic resonance imaging of the same patient, repeated after 1 month. T2-weighted image.](10.1177_2324709620939802-fig1){#fig1-2324709620939802}

Case 2 {#section3-2324709620939802}
======

A 61-year-old woman diagnosed with MS in 1995, onset with right arm paresthesia, and then treated with interferon-β-1b 250 µg every other day for 14 years, switched to natalizumab 300 mg intravenously every 28 days for the occurrence of 3 motor and sensitive relapses in 12 months; JCV stratify test was positive (index = 2.584). After 50 natalizumab administrations, considering the high PML risk, the patient decided to stop natalizumab and to switch to fingolimod. Three months after natalizumab discontinuation, and before fingolimod start, a brain MRI showed 2 new small T2 hyperintense lesions in the left frontotemporal pole along with confluent juxta-cortical lesions of the white matter of the left temporal pole and homolateral insula, with patchy, diffuse contrast enhancement ([Figure 2A](#fig2-2324709620939802){ref-type="fig"}). The patient did not show new neurological signs or symptoms. A further new MRI performed 3 weeks later showed a slight dimensional increase of the confluent temporal lesion ([Figure 2B](#fig2-2324709620939802){ref-type="fig"}).

![(A) Hyperintense lesions in the left frontotemporal pole along with confluent juxta-cortical lesions of the white matter of the left temporal pole and homolateral insula. T2-FLAIR weighted image. (B) Further new magnetic resonance imaging performed 3 weeks later. Note the slight dimensional increase of the confluent temporal lesion. T2-FLAIR weighted image.](10.1177_2324709620939802-fig2){#fig2-2324709620939802}

The patient underwent lumbar puncture to perform JCV-DNA with a high sensitivity test (10 copies of JCV-DNA in 10 µL of CSF), which resulted negative. The remaining cyto-chemical analysis of CSF was normal. A month later, a brain MRI was repeated with no modification of the radiological findings and with spectroscopic evidence of slight decrement of NAA concentration along with a slight increase of choline and lactate-lipids peak concentrations. These findings were confirmed as suggestive for PML with immune reconstitution inflammatory syndrome associated. All expert MS neuroradiologists confirmed a high PML suspect. The clinical and radiological findings remained stable over time and the patient remains asymptomatic.

Discussion {#section4-2324709620939802}
==========

PML is associated with various MS therapies; early PML diagnosis is fundamental to prevent further worsening, since asymptomatic PML patients have a better clinical and functional outcome in comparison to symptomatic ones.^[@bibr5-2324709620939802]^

Regardless of differences in etiology and pathogenesis, PML and MS share certain distinctive and similar MRI findings, including the presence of inflammatory demyelinating lesions in the white matter.^[@bibr6-2324709620939802]^ PML usually appears in MRI as one or more areas of hyperintensity on T2/FLAIR (fluid attenuation inversion recovery) sequences in the white matter with a peripheral, bilateral, and asymmetric distribution. Some lesion could have inside a little irregular signal intensity, which can have a punctate microcystic appearance^[@bibr7-2324709620939802],[@bibr8-2324709620939802]^; this probably represents small areas of demyelination in the immediate nearness of infected oligodendrocytes or early immune response within perivascular spaces.^[@bibr9-2324709620939802]^ PML lesions have typically subcortical rather than periventricular location and affect U-fibers. FLAIR sequence has the highest sensitivity in the identification of PML lesions; T2-weighted sequences can show particular features of PML lesions, such as microcysts.^[@bibr10-2324709620939802]^ T1 with and without contrast sequences are useful to determine the degree of demyelination and signs of inflammation, suggestive for immune reconstitution inflammatory syndrome. Diffusion-weighted imaging sequences are used to detect signs of active infection.^[@bibr10-2324709620939802]^ MS lesions have more frequently an ovoid shape with well-circumscribed borders with a size of generally 3 to 5 mm, whereas PML ones are more diffuse with ill-defined margins and larger size^[@bibr10-2324709620939802]^ (see [Table 1](#table1-2324709620939802){ref-type="table"}).

###### 

Typical Radiological Findings of MS and Asymptomatic PML.

![](10.1177_2324709620939802-table1)

             MS findings                                                                   PML findings
  ---------- ----------------------------------------------------------------------------- -----------------------------------------------------------------
  Location   Periventricular                                                               Cortical gray matter or juxta-cortical white matter involvement
  Shape      Ovoid shape with well-circumscribed borders with a size of generally 3-5 mm   Diffuse, confluent irregular, or infiltrative appearance

Abbreviations: PML, progressive multifocal leukoencephalopathy; MS, multiple sclerosis.

In some cases, JCV-DNA is not detectable in the CSF, as it depends on viral load and on the JCV sensitivity test.^[@bibr1-2324709620939802]^ The gold standard diagnostic tool is a brain biopsy.^[@bibr1-2324709620939802],[@bibr11-2324709620939802]^ However, considering the dangerousness, this procedure is generally not undertaken, unless the PML diagnosis is strictly suspected.^[@bibr11-2324709620939802]^ In our case series, in consideration of the absence of signs and symptoms, brain biopsy was not justified.

At the time there is no specific and effective treatment for PML: the infection outcome depends primarily on the individual's immune reconstitution ability to respond to JCV.^[@bibr12-2324709620939802]^ The mandatory intervention after PML is suspected highlights the immediate withdrawal of the MS drug.^[@bibr13-2324709620939802]^ Hence, the early diagnosis of PML is crucial since patients, restoring immune functions, could have an improvement in terms of survival and sequelae.^[@bibr12-2324709620939802]^ Both patients were diagnosed with suspected PML during a routine brain MRI control; this highlights the importance to provide a strict brain MRI follow-up during dimethyl fumarate treatment, although only a few cases of PML during this therapy have been detected,^[@bibr1-2324709620939802]^ and during natalizumab suspension phase, prior to starting a new MS treatment. We cannot exclude that both patients had an asymptomatic PML, self-limiting. In the second patient, the contrast enhancement and the washout period could suggest a possible MS reactivation.

In a real-life setting, in a radiologically suspected case of PML, although not confirmed by the CSF analysis, the best approach could be to suspend the treatment that could have caused PML and carry out a close radiological and clinical monitoring before starting a new MS therapy.
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